Benign prostatic hyperplasia (BPH), commonly known as prostate enlargement, is a highly prevalent chronic urological condition among aging men. Epidemiological data indicate that more than 50% of men aged 60 and older are affected, with prevalence rising to approximately 83% by age 80.
Characteristic lower urinary tract symptoms—including urinary frequency, urgency, nocturia, weak urinary stream, and straining during urination—not only impair daily functioning but also significantly disrupt sleep architecture and contribute to anxiety, fatigue, and reduced quality of life. In response to this widespread clinical challenge, Aitinglie® (a fixed-dose combination capsule containing finasteride 5 mg and tadalafil 5 mg) has emerged as the first approved combination therapy for BPH in China—filling a critical gap in the therapeutic landscape for men with this progressive disorder.
The dual-mechanism formulation leverages complementary pharmacological actions: finasteride inhibits 5-alpha-reductase, thereby reducing dihydrotestosterone (DHT) levels and inducing gradual prostate volume reduction over months; tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, promotes smooth muscle relaxation in the prostate and bladder neck, yielding rapid symptomatic relief—often within four weeks. Clinical evidence demonstrates that this synergistic approach leads to significantly greater improvements in the International Prostate Symptom Score (IPSS) compared with finasteride monotherapy, offering faster and more comprehensive resolution of obstructive and irritative urinary symptoms.
Aitinglie® is indicated for adult men diagnosed with BPH and associated lower urinary tract symptoms (LUTS). Three patient subgroups derive particularly meaningful benefit:
First, men with confirmed BPH and moderate-to-severe LUTS who require earlier symptom control. While finasteride alone typically requires three to six months to achieve maximal effect, the addition of tadalafil provides clinically meaningful symptom improvement within the first month—enhancing treatment adherence and patient confidence.
Second, men with concomitant erectile dysfunction (ED). BPH and ED frequently coexist due to shared pathophysiological mechanisms—including vascular insufficiency, autonomic dysregulation, and chronic inflammation. Unlike some alpha-blockers or 5-alpha-reductase inhibitors that may adversely affect sexual function, tadalafil in this combination actively improves erectile capacity, enabling simultaneous management of both voiding dysfunction and sexual health.
Third, older adults requiring long-term medical therapy. As BPH is a chronic, progressive condition, sustained pharmacologic intervention is essential. Aitinglie®’s once-daily dosing regimen simplifies treatment, supports consistent adherence, and aligns with the practical needs of aging patients managing multiple chronic conditions.
As with all chronic therapies, regular follow-up with a urologist is essential to monitor symptom progression, assess prostate-specific antigen (PSA) trends, evaluate treatment response, and screen for complications such as acute urinary retention or renal impairment. Lifestyle modifications—including limiting evening fluid intake, avoiding prolonged sitting, moderating alcohol consumption, and smoking cessation—should be integrated into the overall management strategy to optimize therapeutic outcomes.
In summary, Aitinglie® represents a clinically rational, evidence-informed option for appropriately selected men with BPH. Its approval marks an important advancement in personalized, multimodal urological care—particularly for those seeking rapid symptom relief, concurrent ED management, or simplified long-term treatment regimens. Eligibility hinges on accurate diagnosis and alignment with established indications; decisions should always be made collaboratively between patient and clinician.